TAK-003 (Qdenga) Vaccine 💉 | Which Mosquito-Borne Disease Does It Prevent? | Current Affairs 2026

Q. The TAK-003 (QDENGA) vaccine, to be produced in India with Biological E, protects against which mosquito-borne disease?
✅ Answer: Dengue
TAK-003, marketed as Qdenga, is a live-attenuated tetravalent vaccine developed by Takeda for the prevention of dengue. It is designed to provide protection against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). World Health Organization
🔑 Key Facts:
– 🦠 Disease: Dengue
– 💉 Vaccine: TAK-003 (Qdenga)
– 🏢 Developer: Takeda
– 🇮🇳 Indian manufacturing partner: Biological E
– 🧬 Type: Live-attenuated tetravalent dengue vaccine
– 🔬 Coverage: Four dengue virus serotypes
– 🌍 WHO: Recommends TAK-003 for children aged 6–16 years in settings with high dengue transmission intensity. World Health Organization
– 💉 Primary schedule: Two doses administered three months apart. World Health Organization
📚 Important for: UPSC | SSC | Banking | Railway | Defence Exams | State PSC | Current Affairs 2026
#CurrentAffairs2026 #TAK003 #Qdenga #Dengue #DengueVaccine #BiologicalE #HealthCurrentAffairs #ScienceAndTechnology #UPSC #SSC #BankingExams #CurrentAffairsMCQ